New Study Raises Concerns Over Bone Health Risks Linked to Popular Weight Loss Drug, Ozempic

New research has revealed potential long-term health concerns associated with widely used weight loss medications such as Ozempic and Wegovy, highlighting risks that extend beyond their commonly known side effects.

The study, which analysed data from nearly 150,000 patients, found that individuals using GLP-1 medications may face a significantly higher likelihood of developing bone- and tendon-related complications. The findings have sparked fresh debate among medical experts about the long-term safety profile of these increasingly popular treatments.

Increased risk of bone-related conditions
Over a five-year period, researchers observed that users of these medications had nearly a 30 percent higher risk of developing osteoporosis, a condition that weakens bones and makes them more prone to fractures.

The study also noted a 12 percent increase in the risk of gout, a painful form of arthritis caused by uric acid buildup. In addition, a rarer condition that leads to bone softening showed a notable rise among patients on the drugs.

While the findings are concerning, researchers cautioned that the study does not establish a direct cause-and-effect relationship between the medications and these conditions. Instead, they suggest that rapid weight loss and possible nutrient deficiencies linked to the drugs may contribute to the increased risks.

Balancing benefits and risks
Despite the emerging concerns, medical professionals emphasise that GLP-1 medications still offer substantial benefits. These include significant weight loss and a reduced risk of heart disease, making them a valuable option for many patients managing obesity and related conditions.

However, experts are now urging a more cautious approach to their use. Recommendations include regular monitoring of bone health, maintaining proper nutrition, and incorporating strength training exercises to help mitigate potential risks.

As the use of drugs like Ozempic and Wegovy continues to rise globally, the findings underscore the importance of personalised medical guidance and long-term health planning for patients considering or currently using these treatments.